Valbiotis Stock
Price
Target price
€0.97
€0.97
4.520%
0.042
4.520%
-
27.02.26 / Frankfurt
WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Valbiotis Stock
Valbiotis dominated the market today, gaining €0.042 (4.520%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Valbiotis stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Valbiotis in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Valbiotis vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Valbiotis | 4.520% | - | - | - | - | - | - |
| Sensorion SA | 1.980% | 12.975% | - | - | - | - | - |
| Cerenis Therapeutics Holding S.A. | 1.700% | -3.202% | -12.385% | - | -8.528% | - | - |
| Genoway S.A. Inh. | 2.240% | -2.146% | -4.603% | -31.118% | -8.065% | -38.710% | -37.190% |
News
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)
VALBIOTIS SA: Valbiotis announces a major new scientific publication on TOTUM-448, an active substance designed to treat metabolic liver disease (MASLD)